Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 ...

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...

With revenues climbing steadily since 2022, Sarepta is just beginning to reap the benefits of Elevidys’ commercialization. In its most recent quarter, SRPT’s cost of sales was $132.3 million, while ...

Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...

Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare condition that causes muscle weakness ...